Vitarka Therapeutics Ltd

Drug Discovery

Technology type: Platform Technology

Email: [email protected]
Website: https://vitarka.co.uk/
Membership category: Emerging Y1

Innovation House, Innovation Way, Sandwich, Kent, CT13 9FF, United Kingdom

Vitarka Therapeutics Ltd at a glance

Vitarka Therapeutics has engineered an intracellular drug delivery technology, EndoPore, using pore forming proteins for intracellular targets in Oncology, Neuroscience Pain and Neurodegenerative diseases.

About Vitarka Therapeutics Ltd

Our therapeutic cargoes are siRNA, ASO and peptides.

EndoPore delivers up to 80% therapeutic cargo into the cytosol, compared to less than 1% delivered by Lipid NanoParticles.

We are maturing a pipeline of first-in-class therapeutics, in collaboration with Pharma.

Therapeutic area(s)

Pain
Neurology
Oncology

Articles Vitarka Therapeutics Ltd has contributed to

26 November 2024

Vitarka Therapeutics appoints Dr John Beadle as Chairman of the Board

Vitarka Therapeutics Ltd, the EndoPore® cancer therapeutics company, today announced the appointment of Dr John Beadle as the new Chairman of the Board.

Member news

27 January 2022

Guest blog: How Dr Vineeta Tripathi's experience on the Reactor Programme at Discovery Park accelerated her biotech start-up

Dr Vineeta Tripathi, Chief Executive and Chief Scientific Officer, Vitarka Therapeutics talks about the valuable lessons learnt, through her participation in a life sciences development programme, to accelerate her biotech start-up providing novel therapeutics for cancer indications.

Blog